Ardelyx (ARDX)
(Delayed Data from NSDQ)
$6.21 USD
+0.26 (4.37%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $6.21 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARDX 6.21 +0.26(4.37%)
Will ARDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ARDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARDX
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
ARDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say
Other News for ARDX
ARDX Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Ardelyx, Inc. for Potential Securities Law Violations
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
What You Missed On Wall Street This Morning
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
Ardelyx presents additional data on educational needs related to IBS-C